Reduction of Stress-Induced Behavior by Antagonism of Corticotropin-Releasing Hormone 2 (CRH2) Receptors in Lateral Septum or CRH1 Receptors in Amygdala

Journal of Neuroscience

Volumn 22, Issue 7, 2002, Pages 2926-2935

  Bakshi, Vaishali P ^a   Smith Roe, Stephanie ^b   Newman, Sarah M ^a   Grigoriadis, Dimitri E ^c   Kalin, Ned H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Anxiety; Behavioral inhibition; Corticotropin releasing factor; Corticotropin releasing hormone; CRF; Defensive behavior; Freezing

Indexed keywords

ALPHA HELICAL CORTICOTROPIN RELEASING HORMONE ANTAGONIST; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING HORMONE 1 ANTAGONIST; CORTICOTROPIN RELEASING HORMONE 1 RECEPTOR; CORTICOTROPIN RELEASING HORMONE 2 ANTAGONIST; CORTICOTROPIN RELEASING HORMONE 2 RECEPTOR; DEXTRO PHENYLALANINE CORTICOTROPIN RELEASING HORMONE ANTAGONIST; NB 127914; SAUVAGINE; UNCLASSIFIED DRUG; ALPHA HELICAL CORTICOTROPIN RELEASING HORMONE; ALPHA HELICAL CORTICOTROPIN-RELEASING HORMONE; CORTICOTROPIN RELEASING FACTOR; CRF RECEPTOR TYPE 1; CRF RECEPTOR TYPE 2; HORMONE ANTAGONIST; PEPTIDE;

ALPHA HELIX; AMYGDALOID NUCLEUS; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MEGADOSE; DRUG POTENCY; FREEZING; LOCOMOTION; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; SHOCK; STRESS; ANIMAL; ANIMAL BEHAVIOR; BINDING COMPETITION; CYTOLOGY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MOTOR ACTIVITY; PAIN ASSESSMENT; PHYSIOLOGY; SEPTUM PELLUCIDUM; SPRAGUE DAWLEY RAT;

AMYGDALA; ANIMALS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CORTICOTROPIN-RELEASING HORMONE; DRUG ADMINISTRATION ROUTES; HORMONE ANTAGONISTS; MALE; MOTOR ACTIVITY; PAIN MEASUREMENT; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEPTUM OF BRAIN; STRESS;

EID: 0036546691     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-07-02926.2002     Document Type: Article

References (59)

1. Albert DJ, Walsh ML (1982) The inhibitory modulation of agonistic behavior in the rat brain: a review. Neurosci Biobehav Rev 6:125-143.
2. Albert DJ, Walsh ML (1984) Neural systems and the inhibitory modulation of agonistic behavior: a comparison of mammalian species. Neurosci Biobehav Rev 8:5-24.
3. Bakshi VP, Kalin NH (2002) Animal models and endophenotypes of anxiety and stress disorders. In: Neuropsychopharmacology: the 5th generation of progress (Davis KL, Charney D, Coyle JT, Nemeroff C, eds), pp 883-900. New York: Lippincott Williams & Wilkins.
4. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WV, Lee KF (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour are hypersensitive to stress. Nat Genet 24:410-414.
5. Bandler R, Depaulis A, Vergnes M (1985) Identification of midbrain neurones mediating defensive behavior in the rat by microinjections of excitatory amino acids. Behav Brain Res 15:107-119.
6. Behbehani MM (1995) Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46:575-605.
7. Bittencourt JC, Vaughan J, Arias C, Rissman RA, Vale WW, Sawchenko PE (1999) Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRH receptors. J Comp Neurol 415:285-312.
8. Chalmers DT, Lovenberg TW, De Souza EB (1995) Localization of novel corticotropin-releasing factor receptor (CRH2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRH1 receptor mRNA expression. J Neurosci 15:6340-6350.
9. Chan RK, Vale WW, Sawchenko PE (2000) Paradoxical activational effects of a corticotropin-releasing factor-binding protein "ligand inhibitor" in rat brain. Neuroscience 101:115-129.
10. Chen C, Dagnino Jr R, De Souza EB, Grigoriadis DE, Huang CQ, Kim KI, Liu Z, Moran T, Webb TR, Whitten JP, Xie YF, McCarthy JR (1996) Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem 39:4358-4360.
11. Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale W, Gold LH (1999) Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res 835:1-9.
12. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ, Finn DA, Low MJ, Rittenberg MB, Stenzel P, Stenzel-Poore MP (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24:403-409.
13. Cullen MJ, Ling N, Foster AC, Pelleymounter MA (2001) Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology 142:992-999.
14. Davis M, Shi C (1999) The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann NY Acad Sci 877:281-291.
15. Gingrich JA, Hen R (2000) The broken mouse: the role of development, plasticity and environment in the interpretation of phenotypic changes in knockout mice. Curr Opin Neurobiol 10:146-152.
16. Graeff FG (1994) Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz J Med Biol Res 27:811-829.
17. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084.
18. Heinrichs SC, Pich EM, Miczek KA, Britton KT, Koob GF (1992) Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 581:190-197.
19. 2, receptors mediate anxiogenic-like behavior. Regul Peptides 71:15-21.
20. 125I-Antisauvagine-30: a novel, specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology 40:114-122.
21. Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7:605-611.
22. Jones DN, Kortekaas R, Slade PD, Middlemiss DN, Hagan JJ (1998) The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology 138:124-132.
23. Kalin NH, Sherman JE, Takahashi LK (1988) Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res 457:130-135.
24. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F (2000) Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419.
25. Koob GF, Heinrichs SC (1999) A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 848:141-152.
26. Kozicz T, Yanaihara H, Arimura A (1998) Distribution of urocortin-like immunoreactivity in the central nervous system of the rat. J Comp Neurol 391:1-10.
27. Lee EH (1995) Corticotropin-releasing factor injected into the lateral septum improves memory function in rats. Chin J Physiol 38:125-129.
28. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF-2 receptor. Proc Natl Acad Sci USA 98:7570-7575.
29. Liebsch G, Landgraf R, Engelmann M, Lorscher P, Holsboer F (1999) Differential behavioural effects of chronic infusion of CRH1 and CRH2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 33:153-163.
30. 1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharmaceutical Design 5:289-315.
31. Menzaghi F, Howard RL, Heinrichs SC, Vale W, Rivier J, Koob GF (1994) Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 269:564-572.
32. Mitchell AJ (1998) The role of corticotropin-releasing factor in depressive illness: a critical review. Neurosci Biobehav Rev 22:635-651.
33. Moreau JL, Kilpatrick G, Jenck F (1997) Urocortin, a novel neuropeptide with anxiogenic-like properties. NeuroReport 8:1697-1701.
34. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342-1344.
35. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa SI, Nakazato A, Kumagai T, Okubo T, Tomisawa K (1999) Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289:926-993.
36. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. San Diego: Academic.
37. Perrin MH, Vale WW (1999) Corticotropin-releasing factor receptors and their ligand family. Ann NY Acad Sci 885:312-328.
38. Picciotto MR, Wickman K (1998) Using knockout and transgenic mice to study neurophysiology and behavior. Physiol Rev 78:1131-1163.
39. Primus RJ, Yevich E, Baltazar C, Gallager DW (1997) Autoradiographic localization of CRH1 and CRH2 binding sites in adult rat brain. Neuropsychopharmacology 17:308-316.
40. Radulovic J, Ruhmann A, Liepold T, Spiess J (1999) Modulation of learning and anxiety by corticotropin-releasing factor (CRH) and stress: differential roles of CRH receptors 1 and 2. J Neurosci 19:5016-5025.
41. Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993) Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605:25-32.
42. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843-2848.
43. Risold PY, Swanson LW (1997) Connections of the rat lateral septal complex. Brain Res Rev 24:115-195.
44. Rizvi TA, Ennis M, Behbehani MM, Shipley MT (1991) Connections between the central nucleus of the amygdala and the midbrain periaqueductal gray: topography and reciprocity. J Comp Neurol 303:121-131.
45. Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J (1998) Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA 95:15264-15269.
46. Sakanaka M, Magari S, Shibasaki T, Lederis K (1988) Corticotropin-releasing factor-containing afferents to the lateral septum of the rat brain. J Comp Neurol 270:404-415.
47. Siggins GR, Gruol D, Aldenhoff J, Pittman Q (1985) Electrophysiological actions of corticotropin-releasing factor in the central nervous system. Fed Proc 44:237-242.
48. Simonato M, Manservigi R, Marconi P, Glorioso J (2000) Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. Trends Neurosci 23:183-190.
49. Skelton KH, Nemeroff CB, Knight DL, Owens MJ (2000) Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20:1240-1248.
50. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF (1998) Corticotropin-releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102.
51. Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, Koob GF (1996) Appetite-suppressing effects of urocortin, a CRH-related neuropeptide. Science 273:1561-1564.
52. Stark KL, Oosting RS, Hen R (1998) Inducible knockout strategies to probe functions of 5-HT receptors. Ann NY Acad Sci 861:57-66.
53. Swanson LW, Sawchenko PE, Rivier J, Vale WW (1983) Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36:165-186.
54. Swiergiel AH, Takahashi LK, Rubin WW, Kalin NH (1992) Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats. Brain Res 587:263-268.
55. Swiergiel AH, Takahashi LK, Kalin NH (1993) Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res 623:229-234.
56. Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP (2001) Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135-142.
57. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1 Nat Genet 19:162-166.
58. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213:1394-1397.
59. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181.